Claim statement
Ashwagandha has limited human evidence for stress or anxiety outcomes, but that does not make it a universal cortisol fix or risk-free adrenal treatment.
This claim needs careful boundaries around population, endpoint, mechanism, or source quality.
VV Claim Boundary Matrix v1.0
VV Claim Integrity Score
This score evaluates how cleanly the claim is bounded by evidence, source quality, applicability, risk handling, and graph support.
71/100
Supported With Boundaries
- Evidence confidence
- 62/100
- Weight 22%
- Canonical editorial confidence in the reviewed evidence.
- Source quality
- 82/100
- Weight 16%
- Strength of source anchors for the claim lane.
- Applicability
- 58/100
- Weight 14%
- How well the evidence maps to the public claim.
- Boundary clarity
- 92/100
- Weight 16%
- Whether strong, weak, and falsifying versions are explicit.
- Overclaim containment
- 68/100
- Weight 12%
- Whether hype risk is controlled by the claim framing.
- Harm-risk handling
- 68/100
- Weight 10%
- Whether safety, regulatory, or caution context is visible.
- Graph support
- 66/100
- Weight 10%
- Depth of source, study, content, and related-claim links.
Supported With Boundaries. The score is driven by applicability as the weakest dimension and remains bounded by evidence type, claim wording, source/study support, and visible limitations.
How the claim framework works ->Strongest version
Ashwagandha has limited human evidence for stress or anxiety outcomes, but that does not make it a universal cortisol fix or risk-free adrenal treatment.
Weakest version
The evidence does not support turning this into a universal claim for every person or context.
What would change our mind
Larger, better-controlled, independently replicated evidence in the relevant population and outcome lane.
What supports this claim
Early human evidence
Canonical sources and linked study records currently support this claim framing.
What weakens or limits this claim
Limitation
Trials vary by extract, dose, duration, outcome, population, and sponsorship, so findings should not be generalized to every product.
Limitation
Safety boundaries include pregnancy, liver-injury reports, sedation, drug interactions, thyroid context, and product quality.
Limitation
Stress outcome evidence does not validate adrenal fatigue as a diagnosis.
Limitation
Trials vary by extract, dose, duration, outcome, population, and sponsorship, so findings should not be generalized to every product.
Limitation
Safety boundaries include pregnancy, liver-injury reports, sedation, drug interactions, thyroid context, and product quality.
Limitation
Stress outcome evidence does not validate adrenal fatigue as a diagnosis.
Sources
- Ashwagandha stress and anxiety systematic review and meta-analysis - Medicine
- NCCIH: Ashwagandha Usefulness and Safety - National Center for Complementary and Integrative Health
- LiverTox: Ashwagandha - NIDDK LiverTox